NanoViricides Inc. (NNVC)

[drkazmd65]

NanoViricides stock rises on starting drug screening program to fight severe hepatitis in kids
May 16, 2022 9:26 AM ET
NanoViricides, Inc. (NNVC)
By: Ravikash, SA News Editor

NanoViricides (NYSE:NNVC) stock rose premarket on May 16 after the company said it began drug development to fight recent cases of severe pediatric hepatitis.

The company said it began a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F (hAd41-F), believed to be linked with the occurrence of severe hepatitis syndrome in some children, causing liver transplants and deaths.

NanoViricides (NNVC) said it believes it can develop a drug candidate against hAd41-F in a relatively short time, if any existing pipeline candidate or other nanoviricide candidates in its library are found to be effective.

The Shelton, Conn.-based company is developing an antiviral assay for testing these drug candidates against hAd41-F infection in cell cultures in its own BSL2 Virology facility.

NanoViricides (NNVC), however, noted that its top priority remains to start human clinical trials of its COVID-19 drug candidate NV-CoV-2.
The company expects filing of a clinical trial application for COVID-19 to take place soon, but noted that the timelines are outside its control.

NNVC +12.19% to $1.45 premarket May 16